Katia Bencardino
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes, HER2/EGFR in Cancer Research
Most-Cited Works
- → Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer(2012)1,867 cited
- → Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial(2016)993 cited
- → Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)(2017)807 cited
- → KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer(2009)558 cited
- → Assessment of a HER2 scoring system for colorectal cancer: results from a validation study(2015)311 cited
- → Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer(2019)294 cited